Tag: TROPiCS-02
Sacituzumab Govitecan Increases PFS for Patients With Most Common Type of...
Treatment with sacituzumab govitecan (Trodelvy®; Gilead Sciences), an antibody-drug conjugate (ADC), resulted in longer progression-free survival (PFS) compared to physician’s choice of chemotherapy in...